Wells Fargo & Company Werewolf Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 12,846 shares of HOWL stock, worth $24,407. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,846
Previous 12,487
2.87%
Holding current value
$24,407
Previous $30,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding HOWL
# of Institutions
69Shares Held
31.8MCall Options Held
700Put Options Held
500-
Ra Capital Management, L.P. Boston, MA6.14MShares$11.7 Million0.18% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$8.14 Million6.25% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.4MShares$6.46 Million0.42% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$4.54 Million0.79% of portfolio
-
Bank Of America Corp Charlotte, NC2.15MShares$4.09 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $56.1M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...